A 24-month, Prospective, Non-interventional Study to Describe the Long Term, Real-Life Use of BOTOX for the symptomatic treatment of Adults with Chronic Migraine, Measuring Healthcare Resource Utilization, and Patient Reported Outcomes Observed in Practice.
Phase of Trial: Phase IV
Latest Information Update: 10 Sep 2017
At a glance
- Drugs Botulinum toxin A (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Acronyms REPOSE
- Sponsors Allergan
- 10 Sep 2017 Results assessing long term use of Onabotulinumtoxin A (BOTOX) as prescribed by the physician for headache prophylaxis in adults with chronic migraine, were presented at the 2017 International Headache Society.
- 06 Sep 2017 According to an Allergan media release, data from the study will be presented at the upcoming 18th Congress of the International Headache Society (IHC2017).
- 27 Jun 2017 Results of REPOSE study presented at the 3rd Congress of the European Academy of Neurology.